ReviewCancers2024
Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- SEOM-GEICO clinical guidelines on endometrial cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- The Efficacy of Pembrolizumab Immunotherapy in the Treatment of Endometrial Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Evaluation of Punicalagin as a multi‑targeted therapeutic agent against endometrial cancer.International journal of oncology · 2026Article
- PCOS Serum Promotes Endometrial Cancer Cell Proliferation with Partial Involvement of IGF-Associated AKT/mTOR Signaling: A Pilot Translational Study with Exploratory Molecular Insights.International journal of molecular sciences · 2026Article
- Neutrophil extracellular traps (NETosis) in gynecologic cancers: from pathogenesis to therapeutic opportunities: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- GOT1 promotes endometrial cancer progression by regulating ferroptosis through the STAT3-GPX4 axis and attenuating medroxyprogesterone acetate sensitivity.Cancer gene therapy · 2026Article
- Trends and future projections of endometrial cancer burden attributable to high BMI in China: an age-period-cohort analysis based on 1990-2021 data.Journal of gynecologic oncology · 2026Article
- Article
- Biomaterial-enabled multimodal therapy for endometrial cancer: Subtype-guided immuno-metabolic modulation and fertility-conscious regeneration.Materials today. Bio · 2026Article
- Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) in Patients with Gynecological Malignancies: A Systematic Review.Journal of clinical medicine · 2026Review
- Apparent diffusion coefficient values of lymph nodes in endometrial cancer: can they predict lymph node metastases? - a retrospective study.Abdominal radiology (New York) · 2026Observational
- Review
- Network toxicology and bioinformatic investigation of the association between Bisphenol A and endometrial cancer.Scientific reports · 2026Article
- Anti-cancer effect of palmitic acid against the endometrial cancer progression via inducing ferroptosis.Biochemistry and biophysics reports · 2026Article
- Advances in endometrial cancer screening: a comprehensive review of current methods and emerging technologies.International journal of clinical oncology · 2026Review
- Serum expression levels of HOTAIR and miR-646 in endometrial cancer.Oncology letters · 2026Article
- Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma.Discover oncology · 2026Article
- Mutation detection in women diagnosed with endometrial cancer: a next-generation sequencing analysis.Molecular & cellular oncology · 2026Article
- Subtle Intrusion: Minimal Serous Uterine Carcinoma in an Asymptomatic Postmenopausal Patient-A Case Report.Current aging science · 2026Article
- Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Endometrial cancer is the sixth commonest cancer in women worldwide, with over 417,000 diagnoses in 2020. The disease incidence has increased by 132% over the last 30 years and is set to continue to rise in response to an ageing population and increasing global rates of obesity and diabetes. A greater understanding of the mechanisms driving endometrial carcinogenesis has led to the identification of potential strategies for primary disease prevention, although prospective evaluation of their efficacy within clinical trials is still awaited. The early diagnosis of endometrial cancer is associated with improved survival, but has historically relied on invasive endometrial sampling. New, minimally invasive tests using protein and DNA biomarkers and cytology have the potential to transform diagnostic pathways and to allow for the surveillance of high-risk populations. The molecular classification of endometrial cancers has been shown to not only have a prognostic impact, but also to have therapeutic value and is increasingly used to guide adjuvant treatment decisions. Advanced and recurrent disease management has also been revolutionised by increasing the use of debulking surgery and targeted treatments, particularly immunotherapy. This review summarises the recent advances in the prevention, diagnosis and treatment of endometrial cancer and seeks to identify areas for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.